Your session is about to expire
← Back to Search
Phosphodiesterase-V Inhibitor
Sildenafil for DCI
Phase 1
Waitlist Available
Led By Chad W Washington, MS, MD, MPHS
Research Sponsored by University of Mississippi Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
No Placebo-Only Group
Summary
This trial tests whether oral sildenafil is as effective as intravenous sildenafil in reducing vasospasm after aneurysmal rupture, while also causing less hypotension.
Eligible Conditions
- Subarachnoid Hemorrhage
- Cerebral Vasospasm
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Low dose sildenafilExperimental Treatment1 Intervention
Twelve patients with cerebral vasospasm following aneurysmal subarachnoid hemorrhage will be assigned to low dose sildenafil citrate and will receive a 20mg oral dose and a subsequent 10mg intravenous dose of sildenafil citrate.
Group II: High dose sildenafilExperimental Treatment1 Intervention
Twelve patients with cerebral vasospasm following aneurysmal subarachnoid hemorrhage will be assigned to high dose sildenafil citrate and will receive a 60mg oral dose and a subsequent 30mg intravenous dose of sildenafil citrate.
Find a Location
Who is running the clinical trial?
University of Mississippi Medical CenterLead Sponsor
182 Previous Clinical Trials
197,080 Total Patients Enrolled
Chad W Washington, MS, MD, MPHSPrincipal InvestigatorUniversity of Mississippi Medical Center